Assignee
CELGENE AVILOMICS RES INC
US·30 granted patents·19 pending applications·448 citations·filing 2012–2016
Top patents by PatentIndex Score
49 records- 0199US8609679B22,4-diaminopyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Dec 17, 2013·84 cites·4 claims
- 0298US8710222B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Apr 29, 2014·52 cites·3 claims
- 0396US9561228B2ERK inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2014·Granted Feb 7, 2017·37 cites·17 claims
- 0496US9375431B22,4-disubstituted pyrimidine compounds useful as kinase inhibtorsCELGENE AVILOMICS RES INC·Filed 2015·Granted Jun 28, 2016·21 cites·29 claims
- 0596US9212181B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Dec 15, 2015·34 cites·42 claims
- 0695US9409921B22,4-disubstituted pyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2014·Granted Aug 9, 2016·25 cites·2 claims
- 0795US9296737B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Mar 29, 2016·27 cites·23 claims
- 0894US9458175B2MK2 inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Granted Oct 4, 2016·16 cites·32 claims
- 0994US9145387B2ERK inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2014·Granted Sep 29, 2015·21 cites·28 claims
- 1093US9409887B2Mutant-selective EGFR inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2014·Granted Aug 9, 2016·16 cites·26 claims
- 1193US8980935B2HCV protease inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Granted Mar 17, 2015·7 cites·26 claims
- 1292US9504686B2ERK inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Granted Nov 29, 2016·10 cites·40 claims
- 1392US9321786B2Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2014·Granted Apr 26, 2016·15 cites·51 claims
- 1491US9604936B2Besylate salt of a BTK inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Mar 28, 2017·13 cites·14 claims
- 1590US9415049B2Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Granted Aug 16, 2016·12 cites·27 claims
- 1689US9539255B2Solid forms of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2015·Granted Jan 10, 2017·6 cites·31 claims
- 1789US9108927B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Aug 18, 2015·9 cites·20 claims
- 1889US9056839B2Solid forms of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Jun 16, 2015·9 cites·33 claims
- 1989US8748606B24,6-diaminopyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Jun 10, 2014·8 cites·4 claims
- 2088US9540335B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2015·Granted Jan 10, 2017·5 cites·20 claims
- 2185US9422333B2HCV protease inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Granted Aug 23, 2016·2 cites·19 claims
- 2285US9040541B24,6-disubstituted pyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2013·Granted May 26, 2015·5 cites·24 claims
- 2384US9393246B24,6-disubstituted pyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2015·Granted Jul 19, 2016·3 cites·11 claims
- 2483US9067929B2Heterocyclic compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Granted Jun 30, 2015·4 cites·22 claims
- 2577US9126950B2Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Granted Sep 8, 2015·4 cites·24 claims
- 2674US10662195B2Protein kinase conjugates and inhibitorsCELGENE AVILOMICS RES INC·Filed 2016·Granted May 26, 2020·1 cites·1 claims
- 2773US9296704B2Substituted pyrimidines as protein kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2014·Granted Mar 29, 2016·1 cites·5 claims
- 2869US9364476B2Methods of treating a Bruton's Tyrosine Kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2012·Granted Jun 14, 2016·1 cites·26 claims
- 2966US2015031106A1Hcv protease inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2014·Application pending·0 cites
- 3063US2016326216A1Hcv protease inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3160US2017137463A1Hcv protease inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3259US9492471B2Methods of treating a disease or disorder associated with Bruton'S Tyrosine KinaseCELGENE AVILOMICS RES INC·Filed 2013·Granted Nov 15, 2016·0 cites·16 claims
- 3358US2016311780A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3458US2013131105A1Hcv protease inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2012·Application pending·0 cites
- 3557US2016279127A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3652US2015252019A1Heterocyclic compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Application pending·0 cites
- 3751US2017095475A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 3847US2016030426A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 3945US2014142128A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 4045US2015139979A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 4145US2016287588A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 4245US2015064172A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 4344US2016235805A1Hcv protease inhibitors and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Application pending·0 cites
- 4442US9549927B2Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Granted Jan 24, 2017·0 cites·25 claims
- 4541US2015216865A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 4640US2014140991A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 4737US2014142129A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 4832US2017173011A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2015·Application pending·0 cites
- 4931US2016159774A1Heteroaryl compounds and uses thereofCELGENE AVILOMICS RES INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CELGENE AVILOMICS RES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →